Company / Operating Cash Flow per Share
Lineage Cell Therapeutics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.09
FY2025
5-year range
-$0.17 / -$0.09
FY2021-FY2025
Trend
+35.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-0.43 in FY2017 to $-0.09 in FY2025.
Based on SEC 10-K filings.
-0.09 in FY2025.
Improved from $-0.17 to $-0.09 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 35.0% year-over-year.
- Lowest operating cash flow per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.09 | +35.0% |
| FY2024 | -$0.13 | +21.4% |
| FY2023 | -$0.17 | -20.8% |
| FY2022 | -$0.14 | -7.7% |
| FY2021 | -$0.13 | +39.5% |
| FY2020 | -$0.21 | +12.2% |
| FY2019 | -$0.24 | -1.0% |
| FY2018 | -$0.24 | +44.5% |
| FY2017 | -$0.43 | -0.9% |
| FY2016 | -$0.43 | -13.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026